Twenty-three hips (21 @entity1 ) with 30 pelvic @entity690 underwent reoperation and were observed prospectively for 25 to 74 months (average, 40 months) to assess the fate of @entity530 after reoperation. The average radiographic dimensions of the @entity75 were 2.4 x 1.9 cm with the largest lesion measuring 7 x 5 cm. The porous ingrowth acetabular component shell had been left in situ in 15 hips and had been revised in eight. There was no difference in the average lesional size for hips with revised shells compared with those with unrevised shells. In cases where the shell was left in situ, the @entity690 were curetted by working around the component perimeter or through holes in the shell. In 18 hips the @entity79 (s) were grafted with autograft or allograft. Regardless of the management of the acetabular shell or the absence or presence of bone graft, none of the @entity690 have progressed. Twenty-six of the 30 lesions have increased radiographic density. All acetabular components remain radiographically well fixed. There were no new @entity690 . All hips were functioning well, and none have required subsequent reoperation for any reason. There was a statistically significant reduction in the operative time and the amount of @entity190 when the acetabular component was not revised. It does not appear necessary to remove a well fixed and well positioned cementless acetabular component for the treatment of @entity530 . Debridement of periarticular inflammatory tissue and lesional curettage, either with or without bone graft, is effective in managing this type of @entity604 . Revision of the acetabular component shell was associated with a significant increase in operative time and @entity190 . These results support routine radiographic evaluation after total hip arthroplasty to monitor the development of @entity3061 . On the basis of this experience, the authors recommend lesional treatment of progressive @entity530 to avoid more difficult surgery and minimize @entity1 morbidity.

The fate of XXXX after reoperation. No recurrence with lesional treatment.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity75 :: ('MESH:D001927', 'Disease') :: ['lytic lesions'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss'] @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss'] @entity530 :: ('MESH:D010386', 'Disease') :: ['pelvic osteolysis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone defect'] @entity3061 :: ('MESH:D010014', 'Disease') :: ['osteolysis'] @entity690 :: ('MESH:D030981', 'Disease') :: ['osteolytic lesions']
@entity530 :: (MESH:D010386,Disease) :: ['pelvic osteolysis']
